ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut Microbiota-Isoallolithocholic Acid Crosstalk Promotes Calcium Oxalate Kidney Stone Formation via PARP1-Mediated Parthanatos.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bile acids have been implicated in calcium oxalate (CaOx) nephrolithiasis. Here, we employ multi-omics approaches to identify isoallolithocholic acid (isoalloLCA) as the key bile acid elevated in the feces, serum, kidney, and urine of CaOx rats, confirmed by spatial metabolomics. 16S sequencing and metagenomic analyses indicate that elevated isoalloLCA levels in CaOx rats or individuals are likely of microbial origin. Mechanistically, isoalloLCA binds to PARP1 via specific molecular interactions validated by surface plasmon resonance and cellular thermal shift assays. Knockdown of PARP1 by adeno-associated virus microinjection or pharmacological inhibition with PARP1 inhibitor AZD5305 significantly attenuates isoalloLCA-mediated crystal deposition, renal tubular injury, and mitochondrial functional impairment in both the CaOx rat and mouse models. Furthermore, the antibiotic-mediated depletion of the gut microbiota in mice markedly reduced isoalloLCA levels, whereas fecal microbiota transplantationut contributes to isoalloLCA-mediated CaOx stone formation, demonstrating a causal link between gut microbiota and isoalloLCA. In vitro, isoalloLCA promoted oxalate-induced renal tubular epithelial cell injury and parthanatos via targeting PARP1, including DNA damage, excessive PARP1 activation, PAR accumulation, mitochondrial damage, nuclear translocation of AIF and MIF. These findings establish the microbiota-isoalloLCA-PARP1-parthanatos axis in CaOx nephrolithiasis and identify PARP1 as a promising therapeutic target for kidney stone management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.